Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07185321 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

A Phase 1 study of Healthy Volunteer, sponsored by Pulmovant.

Active
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT07185321 is a Phase 1 study of Healthy Volunteer that is active but no longer recruiting, run by Pulmovant. The registered enrollment target is 8 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07185321, a Phase 1 study of Healthy Volunteer, is active but no longer recruiting, sponsored by Pulmovant.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

Conditions Studied

Interventions

  • DEVICE Dry Powder Inhaler
  • DRUG Mosliciguat
  • DRUG 14C mosliciguat

Study Locations (1)

Maryland

  • Pharmaron - Baltimore

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-06-10
Est. Completion 2026-05
Phase Phase 1

Sponsor

Pulmovant

3 total trials

What the Registry Record Tells You About NCT07185321

The ClinicalTrials.gov registry entry for NCT07185321 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (96% lower). The listed sponsor is Pulmovant, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 3 interventions - of which Dry Powder Inhaler is the first listed.

NCT07185321 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT07185321 about?

NCT07185321 is a clinical study titled "A Phase 1 Study of Mosliciguat in Healthy, Adult Males". This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

What is the current status of trial NCT07185321?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-06-10. Estimated completion is 2026-05.

What conditions does trial NCT07185321 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT07185321?

The interventions under investigation include: Dry Powder Inhaler (DEVICE), Mosliciguat (DRUG), 14C mosliciguat (DRUG).

Who is sponsoring clinical trial NCT07185321?

This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07185321 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.